Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Evaluation of electrophysiological parameters variability of iPS-derived cardiomyocytes.

Chantoiseau C, Carriot T, Ballet V, Guillon JM.

J Pharmacol Toxicol Methods. 2019 Sep - Oct;99:106595. doi: 10.1016/j.vascn.2019.05.023. Epub 2019 Oct 17. No abstract available.

PMID:
31963078
2.

Prediction of drug-effects on cardiac repolarization in humans: What can we learn from the past to refine our drug discovery strategies?

Valentin JP, Guillon JM, Hoffman PK, Ortemann-Renon C, Koerner J, Pierson J, Gintant GA, Willard J, Skinner M, Wisialowski T, Pugsley M.

J Pharmacol Toxicol Methods. 2019 Sep - Oct;99:106595. doi: 10.1016/j.vascn.2019.05.115. Epub 2019 Oct 17. No abstract available.

PMID:
31962991
3.

Current nonclinical in vivo safety pharmacology testing enables safe entry to first-in-human clinical trials: The IQ consortium nonclinical to clinical translational database.

Ackley D, Abernathy M, Chaves A, Damiano B, Delaunois A, Foley M, Greiter-Wilke A, Guillon JM, Maher J, Monticello T, Pannirselvam M, Renninger J, Vargas H.

J Pharmacol Toxicol Methods. 2019 Sep - Oct;99:106595. doi: 10.1016/j.vascn.2019.05.152. Epub 2019 Oct 17. No abstract available.

PMID:
31962949
4.

Human organotypic bioconstructs from organ-on-chip devices for human-predictive biological insights on drug candidates.

Cavero I, Guillon JM, Holzgrefe HH.

Expert Opin Drug Saf. 2019 Aug;18(8):651-677. doi: 10.1080/14740338.2019.1634689. Epub 2019 Jul 3. Review.

PMID:
31268355
5.

A Proof-of-Concept Evaluation of JTPc and Tp-Tec as Proarrhythmia Biomarkers in Preclinical Species: A Retrospective Analysis by an HESI-Sponsored Consortium.

Boulay E, Abernathy MM, Chui R, Friedrichs GS, Gendron-Parra N, Greiter-Wilke A, Guillon JM, Koerner JE, Menard A, Steidl-Nichols J, Pierson J, Pugsley MK, Rossman EI, Strauss D, Troncy E, Valentin JP, Wisialowski T, Authier S.

Int J Toxicol. 2019 Jan/Feb;38(1):23-32. doi: 10.1177/1091581818813601. Epub 2018 Dec 19.

PMID:
30567462
6.

In vitro secondary pharmacological profiling: An IQ-DruSafe industry survey on current practices.

Valentin JP, Guillon JM, Jenkinson S, Kadambi V, Ravikumar P, Roberts S, Rosenbrier-Ribeiro L, Schmidt F, Armstrong D.

J Pharmacol Toxicol Methods. 2018 Sep - Oct;93:7-14. doi: 10.1016/j.vascn.2018.07.001. Epub 2018 Jul 17.

PMID:
30030184
7.

Cross-Site Reliability of Human Induced Pluripotent stem cell-derived Cardiomyocyte Based Safety Assays Using Microelectrode Arrays: Results from a Blinded CiPA Pilot Study.

Millard D, Dang Q, Shi H, Zhang X, Strock C, Kraushaar U, Zeng H, Levesque P, Lu HR, Guillon JM, Wu JC, Li Y, Luerman G, Anson B, Guo L, Clements M, Abassi YA, Ross J, Pierson J, Gintant G.

Toxicol Sci. 2018 Aug 1;164(2):550-562. doi: 10.1093/toxsci/kfy110.

8.

Delimitation of the embryonic thermosensitive period for sex determination using an embryo growth model reveals a potential bias for sex ratio prediction in turtles.

Girondot M, Monsinjon J, Guillon JM.

J Therm Biol. 2018 Apr;73:32-40. doi: 10.1016/j.jtherbio.2018.02.006. Epub 2018 Feb 10.

PMID:
29549989
9.

Reminiscing about Jan Evangelista Purkinje: a pioneer of modern experimental physiology.

Cavero I, Guillon JM, Holzgrefe HH.

Adv Physiol Educ. 2017 Dec 1;41(4):528-538. doi: 10.1152/advan.00068.2017.

10.

Identification of Ion Currents Components Generating Field Potential Recorded in MEA From hiPSC-CM.

Raphel F, Boulakia M, Zemzemi N, Coudiere Y, Guillon JM, Zitoun P, Gerbeau JF.

IEEE Trans Biomed Eng. 2018 Jun;65(6):1311-1319. doi: 10.1109/TBME.2017.2748798. Epub 2017 Sep 4.

PMID:
28880155
11.

An evaluation of the utility of LVdP/dt40, QA interval, LVdP/dtmin and Tau as indicators of drug-induced changes in contractility and lusitropy in dogs.

Pugsley MK, Guth B, Chiang AY, Doyle JM, Engwall M, Guillon JM, Hoffmann PK, Koerner JE, Mittelstadt SW, Pierson JB, Rossman EI, Sarazan DR, Parish ST.

J Pharmacol Toxicol Methods. 2017 May - Jun;85:1-21. doi: 10.1016/j.vascn.2017.01.002. Epub 2017 Jan 5.

12.

Comprehensive in vitro Proarrhythmia Assay (CiPA): Pending issues for successful validation and implementation.

Cavero I, Guillon JM, Ballet V, Clements M, Gerbeau JF, Holzgrefe H.

J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:21-36. doi: 10.1016/j.vascn.2016.05.012. Epub 2016 May 24. Review.

PMID:
27233533
13.

The evaluation of drug-induced changes in cardiac inotropy in dogs: Results from a HESI-sponsored consortium.

Guth BD, Chiang AY, Doyle J, Engwall MJ, Guillon JM, Hoffmann P, Koerner J, Mittelstadt S, Ottinger S, Pierson JB, Pugsley MK, Rossman EI, Walisser J, Sarazan RD.

J Pharmacol Toxicol Methods. 2015 Sep-Oct;75:70-90. doi: 10.1016/j.vascn.2015.02.002. Epub 2015 Apr 3.

14.

Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.

Benjamin A, Gallacher DJ, Greiter-Wilke A, Guillon JM, Kasai C, Ledieu D, Levesque P, Prelle K, Ratcliffe S, Sannajust F, Valentin JP.

J Pharmacol Toxicol Methods. 2015 Sep-Oct;75:101-10. doi: 10.1016/j.vascn.2015.01.004. Epub 2015 Jan 29.

PMID:
25637943
15.

Dispersal evolution and resource matching in a spatially and temporally variable environment.

Aguilée R, de Villemereuil P, Guillon JM.

J Theor Biol. 2015 Apr 7;370:184-96. doi: 10.1016/j.jtbi.2015.01.018. Epub 2015 Jan 29.

PMID:
25637766
16.

Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy.

Cavero I, Guillon JM.

J Pharmacol Toxicol Methods. 2014 Mar-Apr;69(2):150-61. doi: 10.1016/j.vascn.2013.12.004. Epub 2013 Dec 19. Review.

PMID:
24361689
17.

Safety pharmacology--current and emerging concepts.

Hamdam J, Sethu S, Smith T, Alfirevic A, Alhaidari M, Atkinson J, Ayala M, Box H, Cross M, Delaunois A, Dermody A, Govindappa K, Guillon JM, Jenkins R, Kenna G, Lemmer B, Meecham K, Olayanju A, Pestel S, Rothfuss A, Sidaway J, Sison-Young R, Smith E, Stebbings R, Tingle Y, Valentin JP, Williams A, Williams D, Park K, Goldring C.

Toxicol Appl Pharmacol. 2013 Dec 1;273(2):229-41. doi: 10.1016/j.taap.2013.04.039. Epub 2013 Jun 1. Review.

PMID:
23732082
18.

How do the top 12 pharmaceutical companies operate safety pharmacology?

Ewart L, Gallacher DJ, Gintant G, Guillon JM, Leishman D, Levesque P, McMahon N, Mylecraine L, Sanders M, Suter W, Wallis R, Valentin JP.

J Pharmacol Toxicol Methods. 2012 Sep;66(2):66-70. doi: 10.1016/j.vascn.2012.03.004. Epub 2012 Apr 1.

PMID:
22510338
19.

A spatially explicit model of sex ratio evolution in response to sex-biased dispersal.

Guillon JM, Bottein J.

Theor Popul Biol. 2011 Sep;80(2):141-9. doi: 10.1016/j.tpb.2011.04.003. Epub 2011 May 6.

PMID:
21570994
20.

[Place and role of safety pharmacology in drug development].

Guillon JM.

Ann Pharm Fr. 2010 Sep;68(5):291-300. doi: 10.1016/j.pharma.2010.05.005. Epub 2010 Jul 7. Review. French.

PMID:
20850000
21.

Modeling thermal influence on animal growth and sex determination in reptiles: being closer to the target gives new views.

Girondot M, Ben Hassine S, Sellos C, Godfrey M, Guillon JM.

Sex Dev. 2010;4(1-2):29-38. doi: 10.1159/000280585. Epub 2010 Feb 2. Review.

PMID:
20130387
22.

The isolated rabbit heart and Purkinje fibers as models for identifying proarrhythmic liability.

Roche M, Renauleaud C, Ballet V, Doubovetzky M, Guillon JM.

J Pharmacol Toxicol Methods. 2010 May-Jun;61(3):238-50. doi: 10.1016/j.vascn.2010.01.011. Epub 2010 Feb 1.

PMID:
20117224
23.

Temperature-dependent sex determination and global change: are some species at greater risk?

Hulin V, Delmas V, Girondot M, Godfrey MH, Guillon JM.

Oecologia. 2009 Jun;160(3):493-506. doi: 10.1007/s00442-009-1313-1. Epub 2009 Mar 10.

PMID:
19277719
24.

Molecular phylogeny of horsetails (Equisetum) including chloroplast atpB sequences.

Guillon JM.

J Plant Res. 2007 Jul;120(4):569-74. Epub 2007 May 3.

PMID:
17476459
26.
27.

Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias.

Cavero I, Mestre M, Guillon JM, Crumb W.

Expert Opin Pharmacother. 2000 Jul;1(5):947-73. Review.

PMID:
11249502
28.

Maternal inheritance of chloroplasts in the horsetail Equisetum variegatum (Schleich.).

Guillon JM, Raquin C.

Curr Genet. 2000 Jan;37(1):53-6.

PMID:
10672445
29.

Preclinical in vitro cardiac electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans?

Cavero I, Mestre M, Guillon JM, Heuillet E, Roach AG.

Drug Saf. 1999;21 Suppl 1:19-31; discussion 81-7. Review.

PMID:
10597865
30.

[Village life in Vichy France].

Guillon JM.

Contemp Fr Civiliz. 1999;23(2):247-64. French. No abstract available.

PMID:
20128121
31.

Preferential reduction in vascular responses to endothelin-1 in rats with streptozotocin-induced diabetes.

Guillon JM, Thiry C, Roach AG, Cavero I.

J Cardiovasc Pharmacol. 1998;31 Suppl 1:S133-7.

PMID:
9595421
32.

Interplay of methionine tRNAs with translation elongation factor Tu and translation initiation factor 2 in Escherichia coli.

Guillon JM, Heiss S, Soutourina J, Mechulam Y, Laalami S, Grunberg-Manago M, Blanquet S.

J Biol Chem. 1996 Sep 13;271(37):22321-5.

33.

Molecular recognition governing the initiation of translation in Escherichia coli. A review.

Schmitt E, Guillon JM, Meinnel T, Mechulam Y, Dardel F, Blanquet S.

Biochimie. 1996;78(7):543-54. Review.

PMID:
8955898
34.

Ischemic myocardial cell protection conferred by the opening of ATP-sensitive potassium channels.

Cavero I, Djellas Y, Guillon JM.

Cardiovasc Drugs Ther. 1995 Mar;9 Suppl 2:245-55. Review.

PMID:
7647029
35.

Late CD8+ lymphocytic alveolitis after allogeneic bone marrow transplantation and chronic graft-versus-host disease.

Leblond V, Zouabi H, Sutton L, Guillon JM, Mayaud CM, Similowski T, Beigelman C, Autran B.

Am J Respir Crit Care Med. 1994 Oct;150(4):1056-61.

PMID:
7921436
36.

Cellular pharmacology of potassium channel openers in vascular smooth muscle.

Quast U, Guillon JM, Cavero I.

Cardiovasc Res. 1994 Jun;28(6):805-10. Review.

PMID:
7923283
37.

Membrane ion channels and cardiovascular ATP-sensitive K+ channels.

Cavero I, Guillon JM.

Cardiologia. 1993 Dec;38(12 Suppl 1):445-52. Review.

PMID:
7517343
38.
39.

Polymyositis and chronic graft-versus-host disease: efficacy of intravenous gammaglobulin.

Hanslik T, Jaccard A, Guillon JM, Vernant JP, Wechsler B, Godeau P.

J Am Acad Dermatol. 1993 Mar;28(3):492-3. No abstract available.

PMID:
8445069
40.

The Escherichia coli fmt gene, encoding methionyl-tRNA(fMet) formyltransferase, escapes metabolic control.

Meinnel T, Guillon JM, Mechulam Y, Blanquet S.

J Bacteriol. 1993 Feb;175(4):993-1000.

41.

Long-term results of monthly inhaled pentamidine as primary prophylaxis of Pneumocystis carinii pneumonia in HIV-infected patients.

Pretet S, Salmon D, Rousseau F, Guillon JM, Taki BE, Roux ME, Belguendouz A, Deleuze J, Morini JP, Gorin I, et al.

Am J Med. 1993 Jan;94(1):35-40.

PMID:
8420298
42.

[Extrapulmonary intrathoracic pneumocystosis. Apropos of 4 cases in HIV positive patients].

Riquet M, Chouaid C, Saab M, Hubsch JP, Guillon JM, Klotz BL, Carnot F.

Rev Pneumol Clin. 1993;49(1):13-6. French.

PMID:
8104357
43.

Minocycline-induced cell-mediated hypersensitivity pneumonitis.

Guillon JM, Joly P, Autran B, Denis M, Akoun G, Debré P, Mayaud C.

Ann Intern Med. 1992 Sep 15;117(6):476-81.

PMID:
1503350
44.

Disruption of the gene for Met-tRNA(fMet) formyltransferase severely impairs growth of Escherichia coli.

Guillon JM, Mechulam Y, Schmitter JM, Blanquet S, Fayat G.

J Bacteriol. 1992 Jul;174(13):4294-301.

45.

Elevated expression of ICAM1 (CD54) and minimal expression of LFA3 (CD58) in Epstein-Barr-virus-positive nasopharyngeal carcinoma cells.

Busson P, Zhang Q, Guillon JM, Gregory CD, Young LS, Clausse B, Lipinski M, Rickinson AB, Tursz T.

Int J Cancer. 1992 Apr 1;50(6):863-7.

PMID:
1372880
46.

Nucleotides of tRNA governing the specificity of Escherichia coli methionyl-tRNA(fMet) formyltransferase.

Guillon JM, Meinnel T, Mechulam Y, Lazennec C, Blanquet S, Fayat G.

J Mol Biol. 1992 Mar 20;224(2):359-67.

PMID:
1373194
47.

Technetium-99m-DTPA aerosol and gallium-67 scanning in pulmonary complications of human immunodeficiency virus infection.

Rosso J, Guillon JM, Parrot A, Denis M, Akoun G, Mayaud C, Scherrer M, Meignan M.

J Nucl Med. 1992 Jan;33(1):81-7.

48.

[Lymphocytic alveolitis in the early stages of HIV infection: correlation with biological and prognostic factors].

Quint L, Autran B, Guillon JM, Parrot A, Denis M, Debre P, Mayaud CM, Akoun GM.

Rev Mal Respir. 1992;9(2):155-62. French.

PMID:
1348863
49.

[Endoscopic case: from diagnosis to therapy. Pseudotumoral pneumonia in broncholithiasis].

Zribi H, Guillon JM, Lacronique J.

Rev Pneumol Clin. 1992;48(4):180-2. French. No abstract available.

PMID:
1296263
50.

[Interaction between angiotensin II and endothelin isoforms in the pithed rat].

Guillon JM, Etiemble E, Chabrier PE, Braquet P.

Arch Mal Coeur Vaiss. 1991 Aug;84(8):1069-73. French.

PMID:
1953251

Supplemental Content

Loading ...
Support Center